Selecting Patients for Treatment with CO-1686

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Atezolizumab can be given subcutaneously and it is a preferred method of delivery by patients with non–small cell lung cancer, according to results from the phase 2 IMscin002 trial.

Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.